Aktiia, a health technology firm based in Neuchâtel, Switzerland that makes optical blood pressure monitors, has raised $30 million in funding.
Redalpine led the investment, with participation from 415 Capital, Khosla Ventures, Molten, Translink Capital, and Verve.
Through the utilization of AI-driven technology, which is presently in use by over 60,000 clients and healthcare organizations, the firm hopes to advance its aim of easing the global burden of hypertension by offering insights into blood pressure control.
Aktiia, a medical device company founded by Drs. Mattia Bertschi (CEO) and Josep Solà (CTO), offers a CE-marked device that is currently available in seven European markets and approved in 44 countries globally.
With its technologies, blood pressure data collecting and machine learning modeling are made simple and innovative, providing individualized, continuous, and medical-grade blood pressure and heart rate data.
With the use of blood pressure data, the firm enables individuals, researchers, and physicians to better understand hypertension and provide individualized patient care.
Daniel Graf was appointed as Aktiia’s new president and board member in conjunction with this funding.
